HGS seeks mAbs, PTV News: Mar 11, 2010




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: HGS seeks mAbs, PTV News: Mar 11, 2010
Released on: March 11, 2010. © PharmaVentures Ltd
Visitors: You are watching a 1 minute preview.
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
Human Genome Sciences in deal with BioInvent to find mAbs for its antigens
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Svein Mathisen
President and CEO
BioInvent
Human Genome Sciences (HGS)
Human Genome Sciences is a biopharmaceutical corporation founded in 1992. Its stated purpose is to "discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs." The company focuses on drug development, as well as drug discovery and currently (as of 2008) has a pipeline of novel compounds in clinical development, including drugs to treat such diseases as hepatitis C, lupus, anthrax disease, cancer, rheumatoid arthritis and HIV/AIDS. It has historically pursued collaborations with other biotechnology and pharmaceutical companies, for development partnerships and technology licensing.
BioInvent
BioInvent is a research-based pharmaceutical company developing innovative antibody drugs to target diseases with unmet clinical need. The company's pipeline currently includes product candidates for the treatment of cancer, thrombosis, atherosclerosis, and inflammatory diseases.